Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

41 public trials 6 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Completed

Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)

NCT01466179

Conditions
Acute Lymphoblastic Leukemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +9 more
Locations
  • City of Hope Duarte, California, United States
  • University of California Los Angeles Los Angeles, California, United States
  • Winship Cancer Institute of Emory University Atlanta, Georgia, United States
  • Rush University Medical Center Chicago, Illinois, United States
View all 39 locations
View Trial Details
Completed

Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

NCT01471782

Conditions
Acute Lymphoblastic Leukemia, Burkitt Lymphoma, DNA Virus Infections, +23 more
Locations
  • Children's Hospital Denver Aurora, Colorado, United States
  • Children's Healthcare of Atlanta at Egleston Atlanta, Georgia, United States
  • Washington University St Louis, Missouri, United States
  • Memorial Sloan Kettering New York, United States
View all 30 locations
View Trial Details
Completed

Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

NCT01741792

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • Universitätsmedizin Göttingen, Germany
  • Universitätsklinikum des Saarlandes Homburg, Germany
  • Universitätsklinikum Schleswig Holstein Kiel, Germany
  • Klinikum der Johannes-Gutenberg Universität Mainz, Germany
View Trial Details
Completed

Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma

NCT00435916

Conditions
Hematologic Diseases, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Mayo Clinic-Arizona Scottsdale, Arizona, United States
  • University of California Los Angeles Los Angeles, California, United States
  • Stanford University Medical Center Palo Alto, California, United States
View all 14 locations
View Trial Details
Completed

Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL

NCT00655837

Conditions
Hematologic Diseases, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Mayo Clinic Arizona Scottsdale, Arizona, United States
  • University of Colorado Aurora, Colorado, United States
  • Oncology Specialists Park Ridge, Illinois, United States
View Trial Details
Completed

Study of SGN-40 in Patients With Refractory or Recurrent Multiple Myeloma

NCT00079716

Conditions
Blood Coagulation Disorders, Blood Protein Disorders, Cardiovascular Diseases, +14 more
Locations
  • James R. Berenson M.D., Inc. West Hollywood, California, United States
  • Rocky Mountain Cancer Center Denver, Colorado, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Cornell University New York, United States
View Trial Details
Completed

A Safety Study of SGN-40 in Patients With Non-Hodgkin's Lymphoma

NCT00103779

Conditions
Hematologic Diseases, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Stanford University Stanford, California, United States
  • University of Miami Miami, Florida, United States
  • Cornell University New York, United States
View Trial Details
Completed

Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple Myeloma

NCT00525447

Conditions
Blood Coagulation Disorders, Blood Protein Disorders, Cardiovascular Diseases, +14 more
Locations
  • Rocky Mountain Cancer Center Denver, Colorado, United States
  • H. Lee Moffitt Cancer Center & Research Institute Tampa, Florida, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Barbara Ann Karmanos Cancer Institute Detroit, Michigan, United States
View Trial Details

Related conditions